In November, Amneal received FDA approval for exenatide, its first generic injectable glucagon-like peptide-1 (GLP-1) agonist ...

Glucagon-like peptide receptor agonists (GLP-1RAs) like Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s ...

Long-term investments in top tech, health, and consumer staples for stability, growth, and reliable returns. Read what ...

A lawsuit filed in the Singapore International Commercial Court is seeking $830 million in damages from KBP, with Novo ...

Natco Pharma and Dr. Reddy's Laboratories are eyeing blockbuster drug–Novo Nordisk’s breakout star Semaglutide, sold under ...

Lilly is testing bimagrumab alone and in combination with Novo's Wegovy -- a mid-stage trial begun before the acquisition -- ...

These three stocks just announced significant quarterly dividend increases that they are set to pay out soon. While they all raised dividends by a minimum of 15%, two announced raises north of 35%.

When celebrities reveal their experiences with newer weight-loss drugs, there are upsides and downsides for patients and ...

Small studies link Ozempic and similar drugs to rare but serious eye conditions. However, experts say there's no need to ...

Shares of weight loss and diabetes medication maker Novo Nordisk (NYSE: NVO) have slumped precipitously over the past 52 ...

Six percent of Americans have used Ozempic, Wegovy and similar drugs. They’re unwitting experimental subjects.

The manufacturer of the weight loss jab Wegovy has been reprimanded for allegedly failing to disclose or accurately report payments to healthcare and patient organisations.